Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P50570
UPID:
DYN2_HUMAN
Alternative names:
-
Alternative UPACC:
P50570; A8K1B6; E7EV30; E9PEQ4; K7ESI9; Q5I0Y0; Q7Z5S3; Q9UPH4
Background:
Dynamin-2, a microtubule-associated protein, plays a pivotal role in cellular processes such as neuron morphology regulation, axon growth, and vesicular trafficking, including endocytosis and cytokinesis. Its ability to bind and hydrolyze GTP contributes to the formation of microtubule bundles and neuronal growth cones, highlighting its significance in cellular dynamics and structure.
Therapeutic significance:
Dynamin-2 is implicated in several neuromuscular and neurodegenerative disorders, including Myopathy, centronuclear, 1, Lethal congenital contracture syndrome 5, and different forms of Charcot-Marie-Tooth disease. Understanding the role of Dynamin-2 in these conditions could lead to the development of targeted therapies, offering hope for patients suffering from these debilitating diseases.